Paris, France, July 6, 2016 – Horama, one of the leaders in ophthalmic diseases gene therapy, announces the appointment of Christine Placet as Managing Director, reinforcing the management team of the company as well as the Board.
Before joining Horama, Christine was Chairman of the Management Board of Trophos, a clinical-stage company developing an innovative treatment addressing spinal muscular atrophy, a rare and debilitating genetic neuromuscular disease without approved treatment. Following positive phase 2/3 results, the company was acquired by Roche in January 2015 for up to 470 M€. After different CFO positions in a number of companies and startups in different industries, Christine Placet now brings Horama more than 25 years of experience in the area of finance and management.
« I am delighted to join Horama and to collaborate with Denis Cayet and the talented scientific founding team at a critical time of the company’s progress », commented Christine Placet.
« I am extremely pleased to welcome Christine as a Managing Director. Her great expertise in finance and corporate development with the pharmaceutical industry brings a very valuable skillset for Horama», added Denis Cayet, President of Horama.
Horama is a clinical stage biopharma company, which develops gene therapy treatments based on AAV vector for the treatment of rare retinal diseases. The company’s portfolio namely includes a clinical stage product and two products that will enter into clinical stage in the upcoming months. Horama was founded in 2014 in Paris by Denis Cayet, on the initiative of academic researchers, who carried out the first gene therapy trial for ophthalmology in 2011. These founder-researchers of Horama (Philippe Moullier, Christian Hamel and Vasiliki Kalatzis – INSERM, Michel Weber and Guylène Le Meur Hospital Center of Nantes) do have the complementary and renowned skills on the international scene.